Sepetaprost Emerging Drug Insight

“Sepetaprost, Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Sepetaprost (DE-126/ONO-9054) for Glaucoma in the 7MM. A detailed picture of the Sepetaprost (DE-126/ONO-9054) for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Sepetaprost (DE-126/ONO-9054) for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Sepetaprost (DE-126/ONO-9054) market forecast, analysis for Glaucoma in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

ONO-9054 is a once-daily prostaglandin eye drop product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect on reducing intraocular pressure, ONO-9054 is expected to provide new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP-lowering effect compared to FP receptor agonists.

ONO-9054 has been demonstrated to be safe and well-tolerated in a single-dose escalation clinical study conducted in healthy volunteers. The present Phase I further assessed the safety and tolerability of ONO-9054 as well as its pharmacokinetic and pharmacodynamics profiles following single and multiple-day dosing in subjects with OHT or primary OAG, and the results showed that it was well-tolerated and elicited dose-dependent reductions in IOP, which were sustained for at least 24 h following 2 weeks of consecutive daily dosing.

The company has completed the Phase II clinical trial of ONO-9054 for the treatment of glaucoma and ocular hypertension in the US. In the future, Santen will seek worldwide manufacturing and marketing approval for ONO-9054.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the Sepetaprost (DE-126/ONO-9054) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on Sepetaprost (DE-126/ONO-9054) regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the Sepetaprost (DE-126/ONO-9054) research and development activity in Glaucoma in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around Sepetaprost (DE-126/ONO-9054).
•  The report contains forecasted sales of Sepetaprost (DE-126/ONO-9054) for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for Sepetaprost (DE-126/ONO-9054) in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Sepetaprost (DE-126/ONO-9054) Analytical Perspective by DelveInsight

• In-depth Sepetaprost (DE-126/ONO-9054) Market Assessment

This report provides a detailed market assessment of Sepetaprost (DE-126/ONO-9054) in Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Sepetaprost (DE-126/ONO-9054) Clinical Assessment

The report provides the clinical trials information of Sepetaprost (DE-126/ONO-9054) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Sepetaprost (DE-126/ONO-9054) dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to Sepetaprost (DE-126/ONO-9054) and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Sepetaprost (DE-126/ONO-9054) in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of Sepetaprost (DE-126/ONO-9054) from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Sepetaprost (DE-126/ONO-9054) in Glaucoma.

Key Questions

• What is the product type, route of administration and mechanism of action Sepetaprost (DE-126/ONO-9054)?
• What is the clinical trial status of the study related to Sepetaprost (DE-126/ONO-9054) in Glaucoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Sepetaprost (DE-126/ONO-9054) development?
• What are the key designations that have been granted to Sepetaprost (DE-126/ONO-9054) for Glaucoma?
• What is the forecasted market scenario of Sepetaprost (DE-126/ONO-9054) for Glaucoma?
• What are the forecasted sales of Sepetaprost (DE-126/ONO-9054) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Glaucoma and how are they giving competition to Sepetaprost (DE-126/ONO-9054) for Glaucoma?
• Which are the late-stage emerging therapies under development for the treatment of Glaucoma?